Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Simone Rivolo, Jane Loftus, Balazs Peter, Marion Fahey & Thitima Kongnakorn. (2023) Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland. Journal of Medical Economics 26:1, pages 963-972.
Read now
Read now
Articles from other publishers (10)
Amany Ibrahim Mohamed Mohamed Attia, Abeer Atef, Nora Badawi, Marise Abdou, Sahar Yassin, Eatemad Helmy & Hoda Atef Abdelsattar Ibrahim. (2022) Growth Velocity and Economic Aspects of Human Growth Hormone Treatment in an Egyptian Cohort with Multiple Pituitary Hormone Deficiency: A Retrospective Minireview. Open Access Macedonian Journal of Medical Sciences 10:B, pages 966-971.
Crossref
Crossref
Raymond Mailhot Vega, Jane Kim, Abby Hollander, Jona Hattangadi-Gluth, Jeff Michalski, Nancy J. Tarbell, Torunn I. Yock, Marc Bussiere & Shannon M. MacDonald. (2015) Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer 121:10, pages 1694-1702.
Crossref
Crossref
Mariel Pizarro, Herman Soto, Mauricio Rodríguez, Rosa María Galindo, Emilio Muciño & Patricia Medina Bravo. (2014) Evaluación económica del uso de rhGH solución inyectable de 36 UI en niños con deficiencia de hormona de crecimiento, síndrome de Turner y síndrome de Prader-Willi en México. PharmacoEconomics Spanish Research Articles 12:2, pages 47-52.
Crossref
Crossref
Luke Rudmik, Yves P. Starreveld, William A. Vandergrift, Sarfaraz M. Banglawala & Zachary M. Soler. (2015) Cost-effectiveness of the endoscopic versus microscopic approach for pituitary adenoma resection. The Laryngoscope 125:1, pages 16-24.
Crossref
Crossref
F. Spandonaro, M. Cappa, R. Castello, F. Chiarelli, E. Ghigo & L. Mancusi. (2014) The impact of real practice inappropriateness and devices’ inefficiency to variability in growth hormone consumption. Journal of Endocrinological Investigation 37:10, pages 979-990.
Crossref
Crossref
Pinchas Cohen, Wayne Weng, Alan D. Rogol, Ron G. Rosenfeld, Anne‐Marie Kappelgaard & John Germak. (2014)
Dose‐sparing and safety‐enhancing effects of an
IGF
‐I‐based dosing regimen in short children treated with growth hormone in a 2‐year randomized controlled trial: therapeutic and pharmacoeconomic considerations
. Clinical Endocrinology 81:1, pages 71-76.
Crossref
Crossref
Stefan Kaspers, Michael B. Ranke, Donald Han, Jane Loftus, Hartmut Wollmann, Anders Lindberg, Mathieu Roelants & Joris Kleintjens. (2013) Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome. Applied Health Economics and Health Policy 11:3, pages 237-249.
Crossref
Crossref
Steven Simoens. (2011) Public health and prevention in Europe: is it cost-effective?. Journal of Pharmaceutical Health Services Research 2:3, pages 151-155.
Crossref
Crossref
Torsten Christensen, Andrew Buckland, Anthony Bentley, Christian Djurhuus & Rachael Baker-Searle. (2010) Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. Clinical Therapeutics 32:6, pages 1068-1082.
Crossref
Crossref
Gary C. Brown, Melissa M. Brown, Heidi C. Brown, Blair Irwin & Zachary Roth. (2009) THE COMPARATIVE EFFECTIVENESS AND COST-EFFECTIVENESS OF INTRAOCULAR 90Sr BRACHYTHERAPY/INTRAVITREAL VEGF INHIBITOR FOR NEOVASCULAR MACULAR DEGENERATION. Evidence-Based Ophthalmology 10:2, pages 107-122.
Crossref
Crossref